Amgen, Pfizer, Roche, Hayman Capital Management autoimmune news

Hedge fund manager Kyle Bass filed an inter partes review (IPR) petition with the Patent Trials and Appeals Board (PTAB) of the U.S. Patent and Trademark Office challenging a patent from Roche that covers autoimmune drug Enbrel etanercept. Amgen, which has exclusive rights to the challenged patent, markets Enbrel in the U.S. and Canada, while Pfizer has rights elsewhere. ...